Reduction in False-Positive Results after Introduction of Digital Mammography: Analysis from Four Population-based Breast Cancer Screening Programs in Spain

Radiology ◽  
2011 ◽  
Vol 258 (2) ◽  
pp. 388-395 ◽  
Author(s):  
Maria Sala ◽  
Dolores Salas ◽  
Francesc Belvis ◽  
Mar Sánchez ◽  
Joana Ferrer ◽  
...  
2011 ◽  
Vol 21 (10) ◽  
pp. 2083-2090 ◽  
Author(s):  
Raquel Zubizarreta Alberdi ◽  
◽  
Ana B. Fernández Llanes ◽  
Raquel Almazán Ortega ◽  
Rubén Roman Expósito ◽  
...  

Cancer ◽  
2013 ◽  
Vol 119 (22) ◽  
pp. 3952-3958 ◽  
Author(s):  
Marta Roman ◽  
Rebecca A. Hubbard ◽  
Sofie Sebuodegard ◽  
Diana L. Miglioretti ◽  
Xavier Castells ◽  
...  

2011 ◽  
Vol 53 (1-2) ◽  
pp. 76-81 ◽  
Author(s):  
Dolores Salas ◽  
Josefa Ibáñez ◽  
Rubén Román ◽  
Dolores Cuevas ◽  
Maria Sala ◽  
...  

Radiology ◽  
2009 ◽  
Vol 253 (2) ◽  
pp. 353-358 ◽  
Author(s):  
Nico Karssemeijer ◽  
Adriana M. Bluekens ◽  
David Beijerinck ◽  
Jan J. Deurenberg ◽  
Matthijs Beekman ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3360
Author(s):  
Nadine Zielonke ◽  
Amarens Geuzinge ◽  
Eveline Heijnsdijk ◽  
Sirpa Heinävaara ◽  
Carlo Senore ◽  
...  

The main benefit of breast cancer (BC) screening is a reduction in mortality from BC. However, screening also causes harms such as overdiagnosis and false-positive results. The balance between benefits and harms varies by age. This study aims to assess how harm-to-benefit ratios of BC screening vary by age in the Netherlands, Finland, Italy and Slovenia. Using microsimulation models, we simulated biennial screening with 100% attendance at varying ages for cohorts of women followed over a lifetime. The number of overdiagnoses, false-positive diagnoses, BC deaths averted and life-years gained (LYG) were calculated per 1000 women. We compared four strategies (50–69, 45–69, 45–74 and 50–74) by calculating four harm-to-benefit ratios, respectively. Screening women at 45–74 or 50–74 years would be less beneficial in any of the four countries than screening women at 45–69, which would result in relatively fewer overdiagnoses per death averted or LYG compared to the reference strategy of 50–69. At the same time, false-positive results per death averted would increase substantially. Adapting the age range of BC screening is an option to improve harm-to-benefit ratios in all four countries. Prioritization of considered harms and benefits affects the interpretation of results.


Sign in / Sign up

Export Citation Format

Share Document